Skip to content

Clinical trial for efficacy and safety of EICUF on reducing body weight and body fat of overweight or obesity subjects

Efficacy and safety of EICUF on reducing body weight and body fat of overweight or obesity subjects; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003809
Enrollment
100
Registered
2019-04-18
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects is randomly allocated to either experimental or placebo group and take test material(Immature Citrus Unshiu extract 1056mg/day) or placebo twice a day, each time 2 capsul

Sponsors

Woogjin Foods
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adult male and female between 20-65 years 2) BMI=25kg/m^2 and <32kg/m^2 3) Subject who voluntarily agrees to participate and sign in informed consent form

Exclusion criteria

Exclusion criteria: 1) Subject with severe cerebrovascular disease (infarct, hemorrage), cardiac disease (angina, myocardiac infarct, heart failure, arrhythmias that require treatment) within recent 6 months. (If that patient's clinical status is stable, they can participate in the clinical trial according to investgator) 2) Subject who was taking drugs that affect body weight within the past month (including absorption inhibitors and appetite suppressants, health functional foods / supplements related to obesity improvement, psychiatric drugs such as depression, beta blockers, diuretics, birth control pills, steroids) 3) Patients with uncontrolled hypertension (systolic BP = 160 mmHg or diastolic BP = 100 mmHg, after 10 minutes of test subjects) 4) Subjects who fasting blood glucose = 126 mg/dL or diabetic patients use of hypoglycemic agent or insulin 5) Subject who TSH = 0.1 µU/ml or = 10 µU/ml 6) Subject who more than 2times the the upper limit of normal Serum creatinine of clinical trial institution 7) Subject who more than 3times the upper limit of normal AST(GOT) or ALT(GPT) of clinical trial institution 8) Subject with severe gastrointestinal disorders that have a problem with taking test material 9) Subject who are admitted to hospital, medication or rehabilitation due to alcohol use disorder ? related disorder, heart disease, central nervous disorder, etc. through medical history 10) Subject who are judged to be unable to exercise due to musculoskeletal disorders 11) Subject who participated in the commercial obesity program within the last 3 months 12) Subject who have participated or planned to participate in other clinical trials within the past month 13) Subject who is pregnant or is lactating or has a pregnancy plan during the period of the clinical trial 14) Subject who the opinion investigator make a judgment to be unsuitable for any other reason

Design outcomes

Primary

MeasureTime frame
Percent Body Fat, Body Fat Mass by DEXA(Dual-energy X-ray absorptiometry)

Secondary

MeasureTime frame
weight;Waist Circumference, Hip Circumferenc, Waist to Hip Ratio;Body Mass Index(BMI);Lean Mass by DEXA(Dual-energy X-ray absorptiometry);Visceral Fat Area, Subcutaneous Fat Area, Taoal Fat Area,Visceral fat / Subcutanesou Fat Ratio by CT;Total Cholesterol, HDL-Cholesterol, LDL-Cholesterol, Triglyceride;Adiponectin, hs-CRP, Leptin;treatment-emergent adverse events(TEAEs);Vital Sign(pulsus, arteriotony);clinical laboratory test(hematologic/chemistry examination, Urinalysis);electrocardiography

Countries

Korea, Republic of

Contacts

Public ContactDoori Choi

Bundang Jesaeng Hospital

xhsldks07@naver.com+82-31-779-5077

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026